The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Hepatitis B in HIV-infected patients
Soriano V, Poveda E, Vispo E, Barreiro P. Clin Liver Dis. 2013 Aug;17(3):489-501. doi: 10.1016/j.cld.2013.05.008. Epub 2013 Jul 8
Source
Department of Infectious Diseases, Hospital Carlos III, calle Sinesio delgado 10, Madrid 28029, Spain. vsoriano@dragonet.es
Abstract
Chronic hepatitis B virus (HBV) infection is common in HIV-positive individuals. Although HBV vaccination is mandatory for HIV-positive individuals with negative-HBV markers, lower rates of protection are achieved. HIV infection accelerates the course of liver disease caused by chronic HBV infection, leading to end-stage hepatic illness and increasing the risk of hepatocellular carcinoma. Anti-HBV active agents, especially tenofovir, improve outcomes. Lamivudine alone should be limited to patients with low serum HBV-DNA levels, since selection of drug resistance often compromises long-term benefits, leads to cross-resistance with other antivirals, and favors the potential emergence of HBV-vaccine escape mutants.